Fifth disease
☆ Muzotsatira za 2022 Stiftung Warentest zochokera ku Germany, kukhutitsidwa kwa ogula ndi ModelDerm kunali kotsika pang'ono kusiyana ndi kuyankhulana kwa telemedicine komwe kulipiridwa.
Wamiyezi 16 wokhala ndi Fifth disease ― Masaya onse awiri amasanduka ofiira, ngati akukwapulidwa, ndipo ziphuphu za maculopapular zimawonekera pathupi.
Erythema pamasaya onse awiri.
References
Fifth disease , yomwe imadziwikanso kuti erythema infectiosum, ndi matenda a virus omwe amayamba ndi human parvovirus B19. Imafala kwambiri mwa ana, nthawi zambiri imakhudza omwe ali pakati pa zaka 4 mpaka 14. Zizindikiro nthawi zambiri zimayamba ndi kutentha thupi pang'ono, mutu, zilonda zapakhosi, komanso kumva ngati chimfine. Ana amatha kukhala ndi zidzolo zofiira pankhope zonga slapped cheeks , pamodzi ndi zidzolo pathupi, mikono, ndi miyendo. Akuluakulu, ululu m`malo olumikizirana mafupa ndi dandaulo wamba, amene angawonekere patatha masabata oyamba matenda. Makamaka, pafupifupi 20 mpaka 30 peresenti ya akuluakulu omwe ali ndi parvovirus B19 sangawonetse zizindikiro zilizonse.
Fifth disease (erythema infectiosum) is a viral infection caused by human parvovirus B19. It is more common in children than adults and usually affects children ages 4 to 14. The disease often starts with mild fever, headache, sore throat, and other flu-like symptoms. Children can also develop a bright red rash on the face that looks like “slapped cheeks”, along with a lacy or bumpy rash on the body, arms, and legs. In adults, joint aches are a common symptom. Rash and joint symptoms may develop several weeks after infection. About 20 to 30% of adults who are infected with parvovirus B19 will not have symptoms.
Fifth disease (erythema infectiosum) is a viral infection caused by human parvovirus B19. It is more common in children than adults and usually affects children ages 4 to 14. The disease often starts with mild fever, headache, sore throat, and other flu-like symptoms. Children can also develop a bright red rash on the face that looks like “slapped cheeks”, along with a lacy or bumpy rash on the body, arms, and legs. In adults, joint aches are a common symptom. Rash and joint symptoms may develop several weeks after infection. About 20 to 30% of adults who are infected with parvovirus B19 will not have symptoms.
Chiwopsezo chopatsira parvovirus B19 kuchokera kwa mayi kupita kwa mwana ndi pafupifupi 33%, ndipo pafupifupi 3% ya amayi omwe ali ndi kachilombo amakumana ndi zovuta mwa ana awo. Mayi akatenga kachilombo ka HIV asanakwane milungu 20 yoyembekezera, mwayi wa mavuto monga mavuto a magazi ndi kuchulukana kwa madzimadzi m’thupi la mwana kumawonjezeka. Kuti tiyambe kuthana ndi matendawa, tiyenera kuyang'ana ngati wodwalayo adakumanapo ndi parvovirus poyesa ma antibodies ena (IgM) . Ngati kuyezetsako sikunasonyeze kuwonekera m'mbuyomu koma kukuwonetsa matenda aposachedwapa, wodwalayo amafunika kuyang'anitsitsa nthawi yomwe ali ndi pakati, kuphatikizapo ultrasound nthawi zonse kuti awone ngati pali vuto linalake la thanzi la mwana.
The rate of vertical transmission during maternal parvovirus B19 infection is estimated at 33%, with fetal complications occurring in 3% of infected women. Fetal complications comprising hemolysis, anemia, and nonimmune hydrops fetalis and fetal loss are more frequent when maternal infection occurs before 20 weeks of gestation. The first step in the management of this patient would be to obtain immunoglobulin (Ig) M and IgG titres against parvovirus to evaluate if the patient has had previous immunity against the disease. If results are negative for IgG but positive for IgM (ie, primary infection), this patient would need close obstetrical monitoring for the following weeks, including serial ultrasounds to rule out fetal anemia and hydrops fetalis.
The rate of vertical transmission during maternal parvovirus B19 infection is estimated at 33%, with fetal complications occurring in 3% of infected women. Fetal complications comprising hemolysis, anemia, and nonimmune hydrops fetalis and fetal loss are more frequent when maternal infection occurs before 20 weeks of gestation. The first step in the management of this patient would be to obtain immunoglobulin (Ig) M and IgG titres against parvovirus to evaluate if the patient has had previous immunity against the disease. If results are negative for IgG but positive for IgM (ie, primary infection), this patient would need close obstetrical monitoring for the following weeks, including serial ultrasounds to rule out fetal anemia and hydrops fetalis.
Fifth disease imayamba ndi malungo otsika, mutu, totupa, ndi zizindikiro zozizira, monga mphuno yothamanga kapena yodzaza. Zizindikirozi zimadutsa, ndiye patapita masiku angapo, zidzolo zimawonekera. Ziphuphu zofiira kwambiri zimawonekera pankhope, makamaka m'masaya. (motero dzina lakuti "matenda a tsaya"). Kuwonjezera pa masaya ofiira, ana nthawi zambiri amakhala ndi zidzolo zofiira, zofiira pa thupi lonse, ndi manja, torso, ndi miyendo zomwe zimakhala zofala kwambiri.
Matendawa nthawi zambiri ndi wofatsa, koma amayi apakati, matenda mu trimester yoyamba wakhala zogwirizana hydrops fetalis, kuchititsa mowiriza padera.
○ Machiritso
Palibe chithandizo chapadera chomwe chimafunikira chifukwa nthawi zambiri chimakhala bwino pakapita nthawi.